- Home
- ZVRA vs ALT Comparison
ZVRA vs ALT Comparison
Compare ZVRA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- ALT
- Stock Information
- Founded
- ZVRA 2006
- ALT 1997
- Country
- ZVRA United States
- ALT United States
- Employees
- ZVRA N/A
- ALT N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- ZVRA Health Care
- ALT Health Care
- Exchange
- ZVRA Nasdaq
- ALT Nasdaq
- Market Cap
- ZVRA 433.5M
- ALT 472.3M
- IPO Year
- ZVRA 2015
- ALT N/A
- Fundamental
- Price
- ZVRA $7.81
- ALT $5.36
- Analyst Decision
- ZVRA Strong Buy
- ALT Strong Buy
- Analyst Count
- ZVRA 8
- ALT 8
- Target Price
- ZVRA $22.29
- ALT $21.00
- AVG Volume (30 Days)
- ZVRA 521.7K
- ALT 3.1M
- Earning Date
- ZVRA 03-11-2025
- ALT 05-08-2025
- Dividend Yield
- ZVRA N/A
- ALT N/A
- EPS Growth
- ZVRA N/A
- ALT N/A
- EPS
- ZVRA N/A
- ALT N/A
- Revenue
- ZVRA $23,612,000.00
- ALT $20,000.00
- Revenue This Year
- ZVRA $281.10
- ALT N/A
- Revenue Next Year
- ZVRA $97.98
- ALT N/A
- P/E Ratio
- ZVRA N/A
- ALT N/A
- Revenue Growth
- ZVRA N/A
- ALT N/A
- 52 Week Low
- ZVRA $4.20
- ALT $5.14
- 52 Week High
- ZVRA $9.76
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- ZVRA 49.43
- ALT 42.05
- Support Level
- ZVRA $7.78
- ALT $5.45
- Resistance Level
- ZVRA $8.33
- ALT $6.16
- Average True Range (ATR)
- ZVRA 0.39
- ALT 0.33
- MACD
- ZVRA -0.01
- ALT 0.02
- Stochastic Oscillator
- ZVRA 52.99
- ALT 35.26
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.